Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia

Andrew H. Wei, Josep Maria Ribera, Richard A. Larson, David Ritchie, Armin Ghobadi, Yuqi Chen, Abraham Anderson, Cedric E. Dos Santos, Janet Franklin, Hagop Kantarjian

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


This study aimed to identify biomarkers for clinical outcomes in a phase 3 clinical study of blinatumomab or chemotherapy in adults with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Patients were randomized 2:1 to receive blinatumomab, a BiTE® therapy, for 4 weeks (9 μg/day cycle 1 week 1, 28 μg/day thereafter) every 6 weeks, or chemotherapy. Baseline blood samples were evaluated to identify biomarkers prognostic (both treatment groups) or predictive (either treatment groups) for overall survival, event-free survival, hematologic remission, minimal residual disease (MRD) response, duration of response, or adverse events. Baseline values were balanced between treatment groups. Prognostic biomarkers were platelets, tumor burden, and percentage of T cells: each 1-log increase in platelets at baseline was prognostic for improved 6-month survival; lower tumor burden was prognostic for hematologic remission; and a higher percentage of CD3+ T-cells was prognostic for MRD response. Consistent with the BiTE mechanism of action, higher percentage of CD45+ CD3+ CD8+ T cells was associated with hematologic remission following blinatumomab. No examined biomarkers were significant for the risk of grade ≥3 adverse events. Incorporating baseline biomarkers into future studies may help to identify subgroups most likely to benefit from blinatumomab.

Original languageEnglish
Pages (from-to)2220-2231
Number of pages12
Issue number8
StatePublished - Aug 2021


Dive into the research topics of 'Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this